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Cole-Carpenter syndrome is a severe bone fragility disorder that is characterized by frequent fractures, craniosynostosis, ocular proptosis,
hydrocephalus, and distinctive facial features. To identify the cause of Cole-Carpenter syndrome in the two individuals whose clinical
results were presented in the original description of this disorder, we performedwhole-exome sequencing of genomic DNA samples from
both individuals. The two unrelated individuals had the same heterozygous missense mutation in exon 9 of P4HB (NM_000918.3:
c.1178A>G [p.Tyr393Cys]), the gene that encodes protein disulfide isomerase (PDI). In one individual, the P4HB mutation had arisen
de novo, whereas in the other themutation was transmitted from the clinically unaffected father whowas amosaic carrier of the variant.
The mutation was located in the C-terminal disulfide isomerase domain of PDI, sterically close to the enzymatic center, and affected di-
sulfide isomerase activity in vitro. Skin fibroblasts showed signs of increased endoplasmic reticulum stress, but despite the reported
importance of PDI for collagen type I production, the rate of collagen type I secretion appeared normal. In conclusion, Cole-Carpenter
syndrome is caused by a specific de novo mutation in P4HB that impairs the disulfide isomerase activity of PDI.Cole-Carpenter syndrome (CCS; MIM 112240) was first
identified by Cole and Carpenter in 1987 who described
two unrelated boys with a strikingly similar phenotype
that was characterized by ‘‘bone fragility, craniosynostosis,
ocular proptosis, hydrocephalus, and distinctive facial
features.’’1 They called this disorder ‘‘a newly recognized
type of osteogenesis imperfecta’’ (OI), but the term
‘‘Cole-Carpenter syndrome’’ has usually been used to refer
to this condition.2 After the initial description of the syn-
drome, only one other similar case has been reported.3
Despite its apparent extreme rarity, CCS is commonly clas-
sified as a separate OI-like disorder.4–6
OI is usually transmitted in an autosomal dominant
fashion and is mostly caused by mutations in COL1A1
(MIM 120150) orCOL1A2 (MIM 120160), the genes encod-
ing collagen type I alpha chains.7 Other dominantly and
recessively inherited forms of OI are rare and can be caused
by mutations in a variety of genes (BMP1 [MIM 112264],
CRTAP [MIM 605497], FKBP10 [MIM 607063], IFITM5
[MIM 614757], LEPRE1 [MIM 610339], PPIB [MIM
123841], SERPINF1 [MIM 172860], SERPINH1 [MIM
600943], SP7 [MIM 606633], TMEM38B [MIM 611236],
WNT1 [MIM 164820]), which are either involved in the
post-translational modification of collagen type I or in
the regulation of osteoblast function.8 Collagen type I pro-
tein analyses in skin fibroblasts were reportedly normal in
the two individuals with CCS where this test was per-
formed.1,3 No further investigations into the molecular
cause of CCS have been reported. The gene defect underly-
ing CCS is thus unclear.
The clinical course of the two individuals described by
Cole and Carpenter was initially reported up to the ages
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The Ameevaluated in our institution (Table S1). Individual 1 was
born to unrelated healthy parents at term and sustained
multiple fractures in the first few months of life. Progres-
sive proptosis and frontal bossing developed in the
following months. Craniosynostosis of the coronal and
frontal sutures was diagnosed and frontal craniectomy
was performed. Communicating hydrocephalus was noted
at 12 months of age requiring a ventriculo-peritoneal
shunt. Teeth were small and had hypoplastic enamel.
When individual 1 was 3 years old, craniofacial surgery
was performed in an attempt to reduce facial deformities.
At 4 years of age, he had normal cognitive development
and, following intramedullary rodding surgery of the left
femur, was able to stand. We first evaluated individual 1
when he was 18 years old. He was using a wheelchair for
all mobility and had severe scoliosis and marked deformity
of the upper and lower extremities. Height was 120 cm
(Z score: 8.4) and lumbar spine areal bone mineral den-
sity was low (Z score: 3.9). Serum levels of calcium, inor-
ganic phosphorus, creatinine, alkaline phosphatase, and
parathyroid hormone were normal. He received four cycles
of intravenous pamidronate infusions over a 12-month
period, with no obvious change in clinical status, even
though lumbar spine areal bone mineral density Z score
increased to 2.4.
Individual 2 was the only son of healthy and non-
consanguineous parents. He was brought to medical atten-
tion at 2 months of age, when the presence of several
fractures, micrognathia, frontal bossing, and ocular prop-
tosis were noted. The anterior fontanel was very large
and contiguous with the posterior fontanel. He developed
communicating hydrocephalus in the first 18 months of
life. He first presented at our institution at 18 years oft of Human Genetics, McGill University and Ge´nome Que´bec Innovation
land, OR 97239, USA
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Figure 1. Radiographic Findings in Indi-
vidual 2 at 18 Years of Age
(A) Lateral skull radiograph showing severe
midface hypoplasia.
(B) The right upper extremity is severely
deformed.
(C) In the lower extremities, both femurs
and tibias have undergone intramedullary
rodding surgery. Epiphyses of both distal
femurs are wide and seem filled with
nodular structures (‘‘popcorn epiphyses’’).
The right femur shows a large cystic area
(asterisk) and no bone is visible in the mid-
shaft area (arrow).
(D) Wide epiphyses of the metacarpal and
digital bones, thin cortices and a cystic
appearance. Some of the end phalanges
seem to be partially resorbed (arrows).age, with severe scoliosis and marked deformity of the
upper and lower extremities with ‘‘popcorn epiphyses’’ in
the distal femur and proximal tibia (Figure 1). He used a
wheelchair for all mobility. Height was 97 cm (Z score:
11.7) and lumbar spine areal bone mineral density
Z score was 5.1. Serum levels of calcium, inorganic phos-
phorus, creatinine, alkaline phosphatase, and parathyroid
hormone were normal. Intravenous pamidronate treat-
ment, given for 3 years, was associated with an increase
in lumbar spine areal bone mineral density Z score to
4.2, and otherwise unchanged clinical status.
Because of the strikingly similar phenotypes of individ-
uals 1 and 2, we hypothesized that the same gene was
mutated in both. Aiming at the identification of the dis-
ease-causing genetic variant, we performed whole-exome
sequencing on genomic DNA of both men after obtaining
approval from the Institutional Review Board of McGill
University and informed consent from the two individ-
uals. We used Agilent SureSelect Human All Exon Kit
version 4 for target enrichment, and 100 bp paired-end
runs on an Illumina HiSeq 2000 device at Genome Quebec
and McGill University Innovation Center, Montreal, Can-
ada, as previously detailed.9 The bioinformatics analysis of
exome sequencing data was carried out as described previ-
ously.10,11 Briefly, we used BWA (v. 0.5.9) for mapping of
100 base pair paired-end reads against the human refer-
ence genome (hg19), Samtools mpileup (version 0.1.17)
for variant calling, and ANNOVAR12 for variants annota-
tion. Amean coverage of 176X (individual 1) and 139X (in-
dividual 2) was obtained for all consensus coding sequence
exons, and 93% of bases were covered by R20 reads as
determined by the Genome Analysis Toolkit. In order to
focus on likely disease-causing variants, we filtered out426 The American Journal of Human Genetics 96, 425–431, March 5, 2015the variants with an allele frequency
>5% in either the 1000 Genomes
database or the NHLBI/NHGRI Exome
Project (v.0.0.14, June 20, 2012). We
also filtered out variants that had pre-
viously been seen in >10 individuals
in our exome database (over 1,000exomes). Finally, we only considered the most protein
damaging variants (frameshift indel, nonsense, missense,
and canonical splice site) for further analysis. This short-
listed 329 and 336 variants in individuals 1 and 2,
respectively.
We first investigated the occurrence of rare variants in
the aforementioned genes that are known to be associated
with autosomal dominant and recessive OI. Only individ-
ual 1 carried a nonsynonymous heterozygous variant
in SERPINH1 (NM_001235.3:c.689A>G [p.Tyr230Cys]).
Although, mutations in this gene were previously linked
to an autosomal recessive form of OI, heterozygous carriers
were reported to be phenotypically healthy.13 Thus, we
concluded that this variant could not be responsible for
the syndrome.
Aiming at the identification of a protein-coding gene
that wasmutated in both individuals, we combined exome
data from both individuals and identified 5 candidate
genes (Table S2). This revealed that the same nonsynony-
mous heterozygous c.1178A>G (p.Tyr393Cys) variant in
exon 9 of P4HB (MIM 176790; NM_000918.3) wasmutated
in both individuals (Figure S1). This variant was not pre-
sent in the databases of dbSNP, 1000 Genomes, the
NHLBI/NHGRI Exome Project, or the Exome Aggregation
Consortium and was not previously seen in our in-house
exome database. Moreover, it was predicted to be
damaging by three different bioinformatics algorithms
(SIFT,14 PolyPhen-2,15 MutationTaster16).
Sanger sequencing confirmed that individual 1 (II-1 in
Family 1, Figure 2A) and individual 2 (II-1 in Family 2)
were both heterozygous for the c.1178A>G change in
P4HB. Sanger sequencing also revealed that neither of
the parents of individual 2 had this variant, suggesting
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Figure 2. Confirmation of the Heterozy-
gous P4HB Mutation in Individuals 1 and
2, and Prediction of Its Impact on PDI
(A) Pedigrees of the families of individual 1
(II-1 in family 1) and individual 2 (II-1 in
family 2) and Sanger sequencing chro-
matogram at the site of c.1178A in P4HB
(indicated by arrows). Individuals 1 and 2
are heterozygous for the c.1178A>C
variant. The chromatograms of the father
of individual 1 indicate the presence of
the c.1178A>C variant with a lower rela-
tive peak size in DNA extracted from
saliva, but not in DNA extracted from
skin fibroblasts.
(B) Amino acid conservation of the Tyr393
residue in PDI (NP_000909.2). Tyr393 and
the following 8 residues are perfectly
conserved among species. Tyrosine at the
corresponding position is also conserved
among the various PDI family members.
(C) Schematic representation of PDI and
of the coding exons of P4HB cDNA
(NM_000918.3). The locations of the
exons are aligned relative to the regions
of PDI that each exon encodes. The posi-
tion of the mutation reported in the pre-
sent study is indicated. The domains of
PDI are represented by a, b, b0, a0. An endo-
plasmic reticulum retention motif (KDEL)
is present at the C terminus.
(D) Model of the critical region in PDI.
Cys397 and Cys400 are the active site res-
idues, which normally form a reversible di-
sulfide bond. When Tyr393 is mutated to
Cys393, the new Cys393 is sterically close
to Cys400 and thus might interfere with
the active site of PDI.that the mutation had arisen de novo in individual 2. In
the father of individual 1 (I-1 in Family 1), Sanger
sequencing of genomic DNA extracted from saliva indi-
cated a c.1178A>G nucleotide change (Figure 2A). How-
ever, the relative height of the peak corresponding to the
variant nucleotide was lower than in his son, suggesting
that the father was mosaic for this mutation. Quantifica-
tion with PeakPicker software17 indicated that this individ-
ual carried the variant in 23% of cells present in saliva.
However, the variant was not found in genomic DNA
extracted from his skin fibroblasts (Figure 2A). Because
he denied any medical problems, and in particular had
not suffered any fractures, no further evaluations were
performed.
The mutation rate for single nucleotide variants is in the
order of 1–23 108 and therefore between 0 and 2 de novo
mutations are typically found in an exome.18,19 Conse-The American Journal of Humanquently, the probability of finding
the identical de novo mutation in
both family 1 and family 2 by coinci-
dence is less than 107. We therefore
concluded that the c.1178A>G
change in P4HB was the disease-
causing variant in individuals 1 and 2.The c.1178A>G variant affects the first nucleotide of
P4HB exon 9. In order to rule out an effect of the mutation
on splicing, we obtained cDNA from skin fibroblasts of in-
dividuals 1 and 2 and performed PCR using primers in
exons 8 and 10 of P4HB. Gel electrophoresis of the result-
ing PCR products revealed a single band of the expected
length (Figure S2), suggesting that splicing was not
affected. We therefore concluded that the c.1178A>G
variant led to a p.Tyr393Cys amino acid substitution in
protein disulfide isomerase (PDI; NP_000909.2), the pro-
tein encoded by P4HB. The affected amino acid residue is
perfectly conserved in the PDI of eukaryotic organisms
and also in other members of the PDI protein family,
thus indicating the functional importance of this residue
throughout evolution (Figure 2B).
PDI is the ubiquitously expressed prototypical member
of the disulfide isomerase family of proteins, which assistGenetics 96, 425–431, March 5, 2015 427
Figure 3. Effect of the p.Tyr393Cys Variant on the Disulfide
Isomerase Activity of PDI
Scrambled RNase A (Scr-RNase) was incubated for 5 min with
1.0 mM of either wild-type PDI (PDI-wt) or PDI carrying the
p.Tyr393Cys variant (PDI-Cys393). RNase activity (final RNase A
concentration: 4 mM) was determined by adding cytidine 20,30-
cyclic monophosphate (cCMP, Sigma-Aldrich) (final concentra-
tion: 2 mM). The hydrolysis of cCMP by active RNase A was
monitored by measuring the absorbance at 296 nm. Changes in
absorbance (means and SE of four independent experiments) are
shown every 5 min.with the correct formation of disulfide bridges in nascent
polypeptide chains and therefore are key enzymes for pro-
tein folding.20,21 PDI also has important functions during
the posttranslational modification of procollagen type I,
acting as a chaperone to prevent aggregation of procolla-
gen alpha chains, and as a support for the procollagen
prolyl 4-hydroxylase alpha subunit, the protein that hy-
droxylates many proline residues on the procollagen type
I alpha chains.22,23 PDI is therefore also referred to as prolyl
4-hydroxylase beta subunit.
The fundamental importance of PDI for eukaryotic
organisms is highlighted by the fact that PDI is essential
for cell viability in yeast.24 It therefore appears likely that
global PDI deficiency is embryologically lethal in mamma-
lians. In accordance with this hypothesis, mice with
homozygous global PDI deficiency have not been re-
ported.25 No Mendelian disorders in humans have been
linked to mutations in P4HB.
PDI comprises two domains (called a and a0) with disul-
fide isomerase activity (Figure 2C). The p.Tyr393Cys
variant is located near the C-terminal reactive center, of
which Cys397 and Cys400 are two key residues.21,26 Pro-
tein modeling showed that the cysteine introduced by
the p.Tyr393Cys variant is in close sterical proximity to
Cys400 (Figure 2D), which led us to hypothesize that the
variant interferes with the disulfide isomerase function of
the C-terminal reactive center.
To test this hypothesis, we used the scrambled RNase A
assay, a widely used method to determine the activity of
enzymes with disulfide isomerase activity.27 Scrambled
RNase A contains random disulfide bonds that can be rear-
ranged by disulfide isomerases to the pattern of native428 The American Journal of Human Genetics 96, 425–431, March 5RNase, thus reestablishing its molecular conformation
and enzymatic activity. RNase activity can then be deter-
mined spectrophotometrically. We produced recombinant
human full-length wild-type PDI as well as PDI with the
p.Tyr393Cys substitution by expression in E. coli and
compared the ability of the two forms of PDI to reactivate
scrambled RNase A. We observed that RNase activity was
clearly lower after incubation with PDI carrying the
p.Tyr393Cys variant (Figure 3). This confirmed that the
p.Tyr393Cys variant impaired the ability of PDI to act as
a disulfide isomerase.
We next assessed the effects of the p.Tyr393Cys variant
in skin fibroblasts. Expression of PDI protein appeared
quantitatively normal in cells carrying the mutation
(Figure 4A). However, when the immunoblot was repeated
under non-reducing conditions, thus preserving disulfide
bridges, additional bands appeared at higher molecular
weight (R100 kD) in fibroblasts with the mutation. These
species were also detected in control cells, but to a much
lesser extent. This suggests that PDI-Cys393 forms more
stable disulfide bridges with substrate proteins than wild-
type PDI.
Because PDI is thought to be important for collagen type
I processing, we evaluated collagen type I production in fi-
broblasts. Delays in collagen type I triple helical formation
typically lead to overmodification of collagen alpha
chains.28 However, no obvious abnormality in migration
pattern of collagen type I alpha chains was found
(Figure S3A), confirming findings that were previously re-
ported by others.1,3 Pulse-chase experiments indicated a
normal rate of secretion of procollagen type I (Figure S3B).
Electron microscopy of fibroblast cultures did not show
obvious abnormalities in the appearance of either cells or
extracellular matrix (data not shown). However, immuno-
fluorescence studies showed a marked increase in the
vesicular pattern of both PDI and procollagen type I distri-
bution in CCS fibroblasts, contrasting with the normal
reticular and Golgi-like staining observed in control cells
(Figure 4B). Immunoblotting showed increased expression
of heat shock protein 47, another collagen chaperone
molecule, suggesting the presence of endoplasmic reticu-
lum stress (Figure 4C).
This study shows that CCS is caused by a heterozygous
de novo mutation in P4HB that is identical in the two
disease-defining individuals. The resulting p.Tyr393Cys
variant leads to a reduction of disulfide isomerase activity
in vitro. However, it appears unlikely that the CCS pheno-
type is simply due to PDI haploinsufficiency in vivo.
Inactivating variants in genes coding for enzymes usually
do not cause a phenotype when heterozygous. Mice with
heterozygous ablation of P4hb were generated in at least
one study and were viable and fertile.25 Importantly, het-
erozygous deletions encompassing the P4HB locus have
been found in apparently healthy humans,29,30 and the
ExAC database lists three premature truncating P4HB vari-
ants, suggesting that PDI haploinsufficiency does not
cause CCS., 2015
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Figure 4. Protein Analyses in Skin Fibroblasts
(A) Western blot of PDI under reducing and non-reducing condi-
tions. The amount of PDI is similar in a control (C), individual 1
(P1), and the father of individual 1 (I-1), regardless of whether
ascorbate is added or not. Under non-reducing conditions
(without addition of dithiothreitol, to preserve disulfide bonds),
additional bands are visible in individual 1, indicating that PDI
with the p.Tyr393Cys variant forms stable disulfide bridges with
other proteins.
(B) Immunofluorescence. PDI and type I procollagen have a more
vesicular pattern in skin fibroblasts from individual 2 (P2) as
compared to the control.
(C) Western blot for HSP47. Accumulation of heat shock protein
47 (HSP47) is increased in fibroblasts from individual 1 (P1) and
2 (P2), suggesting endoplasmic reticulum stress. Ascorbate was
added to the culture to stimulate collagen type I secretion. This
did not have a discernible effect on HSP47 accumulation.The fact that both individuals with CCS had the iden-
tical variant in P4HB and that no other P4HB variants
have been linked to Mendelian disorders in humans also
argues for the hypothesis that a gain in a specific detri-
mental and thus dominant-negative function is required
to cause the CCS phenotype. Our immunoblot experi-
ments of fibroblast protein extract under non-reducing
conditions suggest that formation of more stable disulfide
bridges with other proteins may be one of the new detri-
mental functions of PDI that is introduced by the
p.Tyr393Cys substitution. Cys397 of PDI interacts with
cysteine residues of many substrate proteins and this
interaction is then released by Cys400.31 If the Cys393The Ameintroduced by the p.Tyr393Cys variant interferes with
Cys400, as modeling predicts (Figure 2D), then this
release of PDI from its substrate may be delayed, poten-
tially leading to the accumulation of substantially
more PDI-substrate complexes. Such a mechanism might
explain the apparently dominant-negative effect of the
substitution.
Even though P4HB is ubiquitously expressed, the pheno-
type associated with the p.Tyr393Cys variant is character-
ized mainly by skeletal manifestations and hydrocephalus.
The apparent site-specificity of the phenotype may be ex-
plained by the fact that PDI is only one member of a large
family of proteins with disulfide isomerase activity.20 It is
therefore possible that PDI is particularly important for
the skeleton whereas other disulfide isomerases are more
prominent in other tissues.
Both individuals with CCS had a radiographic appear-
ance of ‘‘popcorn epiphyses’’ in the distal femora. This pre-
sumably reflects disintegrated growth plates, a frequent
finding in severe OI that might be caused by lack of struc-
tural support of growth plates by the rarefied bone tissue.32
The fact that the individuals described here did not have
an obvious clinical benefit from pamidronate therapy
may be explained by the fact that they had reached skeletal
maturity by the time that the treatment was started.
Consequently, there was little scope for preventing bone
deformities and for reshaping compressed vertebral bodies
through growth.
The exact mechanistic link between the p.Tyr393Cys
variant in PDI and the severe bone fragility observed in
the two affected individuals remains to be elucidated.
Even though PDI is thought to be important for
collagen type I formation and most types of OI are
characterized by collagen type I abnormalities, our evalu-
ation of skin fibroblasts from both individuals with
CCS did not reveal clear-cut disturbances in collagen
type I formation. However, the phenotype of CCS sug-
gests that the variant affects bone more than skin. It is
therefore conceivable that the p.Tyr393Cys variant affects
collagen processing more in osteoblasts than in skin
fibroblasts.
In addition, PDI is one of the most abundant proteins in
the endoplasmic reticulum.21,31 The presence of large
amounts of dysfunctional protein in the endoplasmic re-
ticulum might have a cell-toxic effect. In accordance
with this, we observed increased endoplasmic reticulum
stress in skin fibroblasts and these cells also showed an
altered endoplasmic reticulum pattern. Endoplasmic retic-
ulum stress is also a prominent feature of some forms of OI
that are caused by mutations in collagen type I encoding
genes, in particular those that affect the C-propeptide.33
Endoplasmic reticulum stress might lead to osteoblast
apoptosis and thus defective bone formation and bone
fragility, as demonstrated in an OI mouse model.34
Conceivably, therefore, the p.Tyr393Cys variant might
lead to dysfunction of bone formation through multiple
pathways.rican Journal of Human Genetics 96, 425–431, March 5, 2015 429
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